Table 5.
The 456 concomitant drugs with potential risk for SJS and TEN.
| Drugs name and their potential risk category | Number of patients that used concomitant drugs n (%) |
|---|---|
| Medium potential risk | |
| Acetaminophen | 15 (3.3) |
| Ciprofloxacin | 7 (1.5) |
| Isoniazid | 6 (1.3) |
| Ethambutol | 5 (1.1) |
| Pyrazinamide | 4 (0.9) |
| Amoxicillin/cloxacillin | 4 (0.9) |
| Amoxicillin | 2 (0.4) |
| Amiloride-hydrochlorthiazide | 2 (0.4) |
| Cefuroxime | 2 (0.4) |
| Fluconazole | 2 (0.4) |
| Glibenclamide | 2 (0.4) |
| Azithromycin | 1 (0.2) |
| Doxycycline | 1 (0.2) |
| Codeine | 1 (0.2) |
| Hydrochlorthiazide | 1 (0.2) |
| Subtotal | 55 (12.1) |
| Low potential risk | |
| Lamivudine | 167 (36.6) |
| Multivitamin | 20 (43.9) |
| Nifedipine | 3 (0.7) |
| Ibuprofen | 2 (0.4) |
| Cetrizine | 2 (0.4) |
| Prednisolone | 2 (0.4) |
| Amlodipine | 1 (0.2) |
| Amprenavir | 1 (0.2) |
| Tramadol | 1 (0.2) |
| Losartan | 1 (0.2) |
| Ketoconazole | 1 (0.2) |
| Dexamethasone | 1 (0.2) |
| Quinine | 1 (0.2) |
| Tetanus toxoid | 1 (0.2) |
| Subtotal | 204 (44.7) |
| No potential risk | |
| Zidovudine | 141 (30.9) |
| Stavudine | 20 (4.4) |
| Tenofovir | 13 (2.8) |
| Ferrous sulphate | 5 (1.1) |
| Vitamin C | 4 (0.9) |
| Emtricitabine | 4 (0.9) |
| Chlorpheniramine | 2 (0.4) |
| Folic acid | 2 (0.4) |
| Ceftriaxone | 1 (0.2) |
| Chloramphenicol | 1 (0.2) |
| Metronidazole | 1 (0.2) |
| Gentamicin injection | 1 (0.2) |
| Loratidine | 1 (0.2) |
| Vitamin B complex | 1 (0.2) |
| Subtotal | 197 (43.2) |
| Total | 456 (100.0%) |
NPC, National Pharmacovigilance Center; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.